Search clinical trials for: IW-6118

Total 122 results

Rigshospitalet, Denmark

Unknown

Optimization of Interval-training in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Denmark
Cyclerion Therapeutics

Completed

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

Healthy

United States
Ironwood Pharmaceuticals, Inc.

Terminated

Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Dyspepsia | Functional Gastrointestinal Disorders

Belgium, Netherlands
Tisento Therapeutics
Children's Hospital of Philadelphia

Terminated

Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

MELAS

United States
Cyclerion Therapeutics

Terminated

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Achalasia

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

Healthy Volunteers

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

Healthy Volunteers

United States
Rigshospitalet, Denmark

Unknown

Interval-training and Appetite Regulation in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Denmark
NHS Greater Glasgow and Clyde
University of Glasgow; Lamellar Biomedical Ltd

Completed

A Study of Patients With Dry Mouth and Sticky Saliva During Radiotherapy

Xerostomia

United Kingdom
Tisento Therapeutics

Terminated

IW-6463 Safety Study in Healthy Elderly Subjects

Other

Netherlands
Tisento Therapeutics

Completed

A Study of IW-6463 in Healthy Volunteers

Other

Netherlands
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD)

Sickle Cell Disease

United States, United Kingdom, Lebanon
Cyclerion Therapeutics

Completed

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Healthy

United States
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

Diabetic Gastroparesis

United States
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Ironwood Pharmaceuticals, Inc.

Recruiting

Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis | Bladder Pain Syndrome

United States
University of Colorado, Denver

Completed

Compression and Cold Therapy on the Post-Operative Shoulder

Postoperative Pain | Shoulder Pain

United States
Ironwood Pharmaceuticals, Inc.

Completed

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Gastroesophageal Reflux

United States
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

United States, Canada
University of Colorado, Denver

Completed

Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults (B-WELL)

Diabetes | Metabolic Syndrome | Aging

United States
Ironwood Pharmaceuticals, Inc.

Completed

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

Healthy

United States
Ironwood Pharmaceuticals, Inc.

Terminated

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

Canada, United States
Ironwood Pharmaceuticals, Inc.

Completed

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States
Assiut University

Not yet recruiting

Efficacy and Safety of Interwoven Self-Expandable Nitinol Stent for Femropopliteal Arterial Occlusive Diseases

Femoropopliteal Occlusive Disease

Egypt
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

Neoplasms | Neoplasms by Histologic Type

China
Johns Hopkins University
SARcode Bioscience

Terminated

SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy

Pars Plana Vitrectomy | Diabetic Macular Edema (DME)

United States
TaiRx, Inc.

Active, not recruiting

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine Neoplasm

Taiwan
Dow Pharmaceutical Sciences

Unknown

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 (IDP-118)

Plaque Psoriasis

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Cystic Fibrosis

United States
Newave Pharmaceutical Inc

Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Small Lymphocytic Lymphoma | Chronic Myelomonocytic Leukemia-2 | Richter Transformation | T-cell-prolymphocytic Leukemia and other conditions

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Active, not recruiting

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Sinusitis | Nasal Polyps | Polyps

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Completed

Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

China
Merck Sharp & Dohme LLC

Completed

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

Lymphoma | Solid Tumor

United States, Israel
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Completed

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

Healthy

United States
Monopteros Therapeutics Inc.

Recruiting

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
AbbVie
KU Leuven; Syndesi Therapeutics

Completed

A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect

Cognitive Disorders

Belgium
Alios Biopharma Inc.

Terminated

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Hepatitis C

Belgium
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Completed

Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis

Dermatitis, Atopic

China
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Psoriasis

United States
Chugai Pharma USA

Completed

Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

Gastroparesis

United States
InQpharm Group

Withdrawn

Vasoactive Effects of IQP-AS-118 in Healthy Individuals

Cardiovascular Disease | Blood Flow

Germany
InQpharm Group

Completed

Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol

Blood Pressure | Low Density Lipoprotein Cholesterol Level

Germany
Cyclerion Therapeutics

Completed

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
Laboratorios Sophia S.A de C.V.

Withdrawn

Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis (PRO-118)

Conjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic Conjunctivitis

Mexico
Codexis Inc.

Completed

Safety and Tolerability of CDX-6114 in Healthy Volunteers

Healthy

Australia
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama

Search clinical trials for: IW-6118

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations